Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification

NCT07196644 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT07196644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07196644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Recruiting
Start date
December 1, 2025
Completion date
December 31, 2030
Enrollment
100 (estimated)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors harboring met amplification